SI-BONE Stock Gains Analyst Backing with $26.41 Price Target Following TD Cowen Coverage Launch

On January 27, 2026, TD Cowen initiated coverage of SI-BONE, a publicly traded medical device company, with a Buy rating. This analyst coverage launch marks a significant moment for the stock, which is generating substantial investor interest. Fintel’s latest research platform data reveals crucial insights into institutional positioning and market sentiment surrounding the Nasdaq-listed shares.

Significant Upside Signals in Analyst Valuation

The coverage initiation brings optimistic projections for SI-BONE’s near-term performance. As of January 14, 2026, analysts have established an average one-year price target of $26.41 per share, representing potential appreciation of 54.06% from the latest closing price of $17.14. This upside potential is noteworthy, with forecasts ranging from a conservative $23.23 to a more bullish $33.60, reflecting diverse analyst perspectives on the company’s trajectory.

SI-BONE’s financial projections show projected annual revenue of approximately 192 million dollars, a modest decrease of 1.01% year-over-year. The non-GAAP earnings per share estimate stands at -1.70, indicating the company remains in investment phase. Despite the negative near-term EPS, the price target uplift suggests market confidence in future profitability.

Share Holdings Show Mixed Institutional Sentiment

Institutional investors demonstrate nuanced positioning in SI-BONE stock. Currently, 343 funds and institutions maintain reportable positions in the company, though this represents a decline of 25 owners (6.79%) from the previous quarter. The average portfolio weight dedicated to SIBN across all institutional funds is 0.13%, which has grown by 10.40%, suggesting increased allocation intensity among existing holders.

Total shares held by institutional investors expanded by 1.64% in the last three months, reaching 52,170 thousand shares. This growth indicates gradual accumulation despite the reduction in the number of institutional holders, suggesting that remaining holders are increasing their stakes.

Stock Sentiment Indicators Point to Positive Outlook

The put/call ratio for SI-BONE shares stands at 0.09, a decidedly bullish signal indicating that market participants are more bullish on the stock than bearish. This metric reflects optimistic sentiment among options traders regarding the stock’s directional movement.

Major institutional stakeholders reveal diverse positioning strategies. American Century Companies maintains the largest position with 2,838 thousand shares representing 6.54% ownership—an increase of 18.38% from its prior filing. However, the firm reduced its portfolio allocation in SIBN by 10.26% during the last quarter, suggesting a strategic rebalancing despite the increased shareholding.

Brown Advisory holds 2,773 thousand shares (6.39% ownership), down from 2,913 thousand shares previously, representing a 5.04% reduction. The investment advisor significantly decreased its portfolio allocation by 70.23%, indicating a notable de-emphasis of this holding within its investment strategy.

Orbimed Advisors maintains a stable position with 2,579 thousand shares representing 5.94% ownership, showing no changes in the last quarter. Champlain Investment Partners holds 2,109 thousand shares (4.86% ownership), down slightly by 1.48% from prior filings, with a 16.74% reduction in portfolio allocation weighting.

First Light Asset Management rounds out major stakeholders with 1,918 thousand shares representing 4.42% ownership—up 8.70% from the prior quarter. Despite the increased share count, the firm reduced its portfolio allocation in the stock by 37.71%, mirroring the pattern of increased shareholdings paired with reduced portfolio emphasis seen among other institutional investors.